AQST financials
Aquestive Therapeutics (AQST) financials: revenue, profit and margins by year and quarter, the balance sheet and cash flow.
AQST income statement, yearly
| Year | Revenue | Gross profit | Operating income | Net income | EPS |
|---|---|---|---|---|---|
| 2025 | $44.55M | $27.39M | -$69.65M | -$83.78M | -0.76 |
| 2024 | $57.56M | $39.69M | -$30.77M | -$44.14M | -0.51 |
| 2023 | $50.58M | $29.75M | -$15.10M | -$7.87M | -0.13 |
| 2022 | $47.68M | $28.29M | -$42.07M | -$54.41M | -1.12 |
| 2021 | $50.83M | $35.84M | -$34.68M | -$70.54M | -1.85 |
| 2020 | $45.85M | $32.88M | -$42.89M | -$55.78M | -1.66 |
- AQST revenue was $44.55M in fiscal 2025, net income -$83.78M.
Updated 2026-11-05 12:51 UTC